中药Ⅰ号方对阿尔兹海默病的多靶位治疗作用

The multitargeted therapeutical effects of Prescription No.1 (PN-1) on Alzheimer's disease

目的应用高通量抗体芯片技术(KinexTM Antibody Microarray)来研究中药I号方(PN-1)对阿尔兹海默病的治疗作用。方法将阿尔兹海默病模型小鼠分为两组,其中对照组4只,每天给予双蒸水灌胃,给药组8只每天给予中药提取物灌胃,给药3个月后,利用KinexTMAntibody Microarray筛选出两组的差异表达蛋白,然后用Ingenuity Pathway Analysis(IPA)及查阅文献找到其中与阿尔兹海默病相关的蛋白分子。结果给予中药I号方(PN-1)的阿尔兹海默病小鼠与空白对照小鼠比较,差异表达蛋白其中与阿尔兹海默病相关,且存在变化的为:p-tau(T522)、COX2,caspase6和caspase9下降;bcl-xl和CaMK4升高。结论中药Ⅰ号方(PN-1)能从抗tau蛋白高磷酸化、抗炎、抑制凋亡和提高记忆力等多靶位改善阿尔兹海默病模型小鼠的病理生理表现,可能成为治疗阿尔兹海默病的有效药物。

Objective To investigated the therapeutical effects of Prescription No. 1 （PN-1） on Alzheimer＇ s disease by KinexTM Antibody Microarray which is a kind of high-throughput antybody microarray. Methods The Alzheimer＇ s disease mouse models are divided into treatment group and control group. There are 8 mouse in the treatment group and given once PN-1 every day by intragastric administration for 3 months, The 4 in the control group are given double distilled water every day by intragastric administration for 3 months too. The different expression protein between the two groups are screened by Kinex^TM Antibody Microarray, the molecules relevant Alzheimer＇ s disease is determined by Ingenuity Pathway Analysis（IPA） and critical review of literatures. Results Compared to control group, the proteins of themouse in the treatment group which are associated with Alzheimer＇ s disease and have different expression between the two groups： p-tau （T522）, COX2, Caspase6 and Caspase9 which are decreased; Bcl-xl and CaMK4 which are increased. Conclusions Prescription No. 1 （ PN-1 ） can ameliorate the pathophysiological performance of Alzheimer＇ s disease mouse models by inhibiting the hyperphosphorylation of tau , inflammatory response, neuronal apoptosis and improving memory, is multitargeted,and may be an effective drug treatment for Alzheimer＇ s disease.